BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Sees Significant Decrease in Short Interest

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 15,720,000 shares, a drop of 9.1% from the December 31st total of 17,290,000 shares. Based on an average daily volume of 2,050,000 shares, the short-interest ratio is presently 7.7 days.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

Several hedge funds have recently bought and sold shares of BCRX. Fisher Asset Management LLC increased its holdings in BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company’s stock valued at $25,369,000 after buying an additional 481,359 shares during the period. BNP Paribas Financial Markets grew its holdings in shares of BioCryst Pharmaceuticals by 472.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 496,784 shares of the biotechnology company’s stock valued at $3,776,000 after purchasing an additional 409,938 shares during the last quarter. Principal Financial Group Inc. grew its holdings in shares of BioCryst Pharmaceuticals by 1,058.1% during the 3rd quarter. Principal Financial Group Inc. now owns 411,414 shares of the biotechnology company’s stock valued at $3,127,000 after purchasing an additional 375,890 shares during the last quarter. Cinctive Capital Management LP bought a new stake in shares of BioCryst Pharmaceuticals during the 3rd quarter valued at approximately $2,082,000. Finally, Two Sigma Advisers LP grew its holdings in shares of BioCryst Pharmaceuticals by 13.6% during the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company’s stock valued at $16,576,000 after purchasing an additional 261,500 shares during the last quarter. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Price Performance

BCRX stock opened at $7.90 on Monday. BioCryst Pharmaceuticals has a 12 month low of $4.03 and a 12 month high of $8.88. The company’s 50-day moving average price is $7.63 and its two-hundred day moving average price is $7.69.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The firm had revenue of $117.10 million during the quarter, compared to the consensus estimate of $113.99 million. During the same period in the prior year, the business earned ($0.19) earnings per share. BioCryst Pharmaceuticals’s quarterly revenue was up 35.1% compared to the same quarter last year. On average, sell-side analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. JMP Securities reissued a “market outperform” rating and set a $18.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday. Evercore ISI increased their price objective on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Needham & Company LLC increased their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Monday, January 13th. Barclays increased their price objective on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 5th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $15.50.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.